Press Release: Sanofi Ventures announces multi-year capital commitment from Sanofi, increasing evergreen fund to $750M
Sanofi Ventures announces multi-year capital commitment from Sanofi, increasing evergreen fund to $750M
- Fund focuses on early stage investing, company co-creation, leading financing rounds and is committed to continuing its investment reach by prioritizing companies advancing innovation
Paris, January 11,2023Sanofi Ventures has announced an additional multi-year commitment from Sanofi, with an increase in capital to more than $750 million to the evergreen venture fund. In addition to serving as a financial partner to top-tier early-to-mid-stage portfolio companies, the fund supports future efforts for business development and M&A opportunities within Sanofi. The additional capital, confirmed by the executive committee, will also fuel the expansion and investment capacity of the Sanofi Ventures investment team on a global scale.
Chief Executive Officer, Sanofi
“Sanofi’s purpose in chasing the miracles of science reaches far beyond our labs. As we continue to build our best-in-class pipeline, we are investing in early stage companies that share our ambition of delivering transformative science and digital innovation. This capital commitment signals Sanofi’s accelerated ambitions in the venture capital community and our continued desire to collaborate with global innovators in the best interests of patients.”
Jason P. Hafler
Managing Director, Sanofi Ventures
“We are grateful for Sanofi’s support over the past decade and appreciate their renewed commitment to early stage innovations that will fuel the next generation of transformative companies aiming to improve the lives of patients.”
Sanofi Ventures invests in top innovators working in areas including immunology and inflammation, rare diseases, oncology, cell and gene therapy, vaccines, and digital health and data science. The team partners across all stages of the private company lifecycle, from Seed to Series B and beyond, leading financings, serving on boards, and taking pride in working alongside portfolio companies to drive long-term value.
In 2022, Sanofi Ventures closed 10 investments in global therapeutic and digital areas of strategic interest to Sanofi. Since its inception, 80% of investments have been in biotherapeutics and 20% have been in digital health companies.
We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.
Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY
Sanofi Investor Relations
Eva Schaefer-Jansen | + 33 7 86 80 56 39 | firstname.lastname@example.org
Arnaud Delépine | + 33 06 73 69 36 93 | email@example.com
Corentine Driancourt | + 33 06 40 56 92 21 | firstname.lastname@example.org
Felix Lauscher | + 1 908 612 7239 | email@example.com
Priya Nanduri | + 1 617 764 6418 | firstname.lastname@example.org
Nathalie Pham | + 33 07 85 93 30 17 | email@example.com
Sanofi Forward-Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the fact that product candidates if approved may not be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi’s ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that COVID-19 will have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2021. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Irish MedTech Company Medihive Receives €7 Million Investment6.2.2023 17:00:00 CET | Press release
The business is now valued at €62 million following the investment. Medihive includes Ireland's largest online doctor service WebDoctor.ie. The investment will be used to fuel international growth, drive R&D innovation and accelerate healthcare software developments. Medihive will recruit up to 42 key hires across sales, engineering, doctors and marketing departments, adding to the 130 people already working with the company. DUBLIN, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Medihive, Ireland's award-winning health technology platform, which includes Webdoctor.ie, has secured an investment from ResMed, an international leader in digital health and cloud-connected medical device innovation, as well as existing shareholders including VentureWave Capital. The investment now values the business at €62 million. Medihive is a software company built to transform medical processes that don't work so patients can benefit from healthcare that does work. The business provides sophisticated software and c
Icelandair: Traffic Data January 20236.2.2023 16:59:28 CET | Press release
In January 2023, Icelandair’s passengers were 210 thousand, compared to 113 thousand in January last year. Capacity in January was 93% of January 2020 levels, the last normal operating January before the pandemic, and 79% of 2019 levels. Passengers on international flights were 191 thousand, compared to 102 thousand in January 2022, an increase of 88%. Passengers to Iceland were 75 thousand and from Iceland 47 thousand. Via passengers were around 69 thousand. On-time performance on international flights was 75%. On time performance and passenger numbers were affected by weather related disruptions in January. The load factor on international flights improved significantly from 59.5% in January 2022 to 74.6% in January this year. Passengers on domestic flights were 18,500, compared to around 12 thousand in January 2022. On time performance was 84%. Load factor on domestic flights was 72.4%. Weather in Iceland caused disruption in the domestic network in January, affecting on time perfor
Acronis builds on partner momentum with Alex Ruslyakov named a 2023 CRN Channel Chief6.2.2023 16:05:00 CET | Press release
Acronis #CyberFit Partner Program kicks off 2023 with new innovations to fuel rapid growth and global expansion BURLINGTON, Mass., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Today, Acronis is honored to announce that CRN®, a brand of The Channel Company, has again recognized Alex Ruslyakov on its 2023 Channel Chiefs list. Acronis’ partner programs have seen tremendous growth over the past year, and Ruslyakov's spot on this year’s list further signifies the program's continued momentum. Acronis has focused heavily on improving partner services and programs over the last year. In 2022, more than 3,500 new service providers joined Acronis’ #CyberFit Partner Program – consisting of service providers, resellers, developers and ISVs, OEM, and affiliate partners. This large number of new registrants is a testament to Ruslyakov's leadership, partner-first approach, and his team's effectiveness in helping MSPs accelerate their business growth with robust sales, marketing, and technical support day in an
Floatgen achieves continuous capacity factor of nearly 60%6.2.2023 16:03:30 CET | Press release
BW Ideol is pleased to announce continuously strong operational results from its 5-year-old Floatgen demonstrator, showing a capacity factor of nearly 60% over the last three months and a production of 25GWh since its 2018 commissioning. France’s first and only floating wind turbine continues to prove its reliable performance capabilities and delivered an average capacity factor of 59.2% over a 3-month period ranging from November 2022 to January 2023. The 25 GWh-milestone was reached just after the major Atlantic storm Gerard in late January. The Floatgen turbine, mounted on BW Ideol’s patented Damping Pool® foundation, handled wind speeds up to 37.30 metres per second (equivalent to 134 km/h) and up to 5.5 metres of significant wave height (equivalent to around 10.5 meters maximum wave height). “Floatgen – one of the few floating wind turbines currently in operation across the globe – continues to deliver outstanding results in terms of reliability, efficiency and production. It keep
World Youth Forum Launches Large Package of Development Initiatives and Projects6.2.2023 16:01:23 CET | Press release
The World Youth Forum announced that this year's sponsorship revenues will support initiatives that contribute to development and increase the quality of life for citizens. Sponsorship revenues will go to supporting entrepreneurship, food security, empowering youths, migrants, mental health and voluntarism. The projects will be implemented in cooperation with leading international organizations and with WYF National and international partners. CAIRO, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Dr. Rascha Ragheb, the executive director of the World Youth Forum, announced that the fifth edition of the WYF will not be launched in its traditional annual format due to the recent successive global crises and their humanitarian and economic repercussions. Instead, the proceeds from sponsorship revenues will be directed towards implementing a large package of development initiatives and programs that have a direct impact on citizens and young people, both in Egypt and the world, in cooperation with the